Amazing, one of the smallest biotechs in Australia, announce a stunning result against Renal Cell Cancer in their first phase 1 trial. Then they are granted orphan drug status in the US by the FDA, with all the commercial benefits that entails, and the price does not move.
To my knowledge there are only a few Bios in Australia have ever been granted orphan drug status. The news was met with substantial market cap increases following those announcements. Companies with large market caps.
One would have thought it would have made a difference to Solbecs tiny market cap.
I hate to see long standing shareholders selling out at this price. Its almost like theft.
Just my opinion.
NS-here is the link to the ADR site I have-http://www.adrbny.com/dr_profile.jsp?cusip=83414N105
Cheers
- Forums
- ASX - By Stock
- SBP
- fda grants orphan drug to coramsine
SBP
solbec pharmaceuticals limited
fda grants orphan drug to coramsine, page-10
Add SBP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
Previous Video
Next Video
SPONSORED BY The Market Online